

# Report of the 20<sup>th</sup> Single Antigen, Flow and Virtual Crossmatch Exchange

## February 1, 2021

Cells	115-116
Serum	117-120

For Exchange 20, Serum 114 (patient 2) and virtual donor V1 from Exchange 19 (June 2020) were re-examined as serum 117 and cell 115. A comparison of virtual crossmatch (VXM) predictions (serum 114 vs. V1) against the physical flow crossmatch (FXM) (**serum 117 vs. cell 115**) are summarized in **Part 1** of this report. **Part 2** examines the single antigen da-

ta for the 4 sera examined (**serum nos. 117 - 120**) in this study. **Part 3** summarizes the flow crossmatch results for 2 cells (**cell nos. 115 - 116**) against the 4 sera. Finally, in **Part 4**, the virtual crossmatch predictions for 4 potential donors (V1 - V4) against 2 sera (serum 119 and serum 120) are examined.

## Part 1

### Physical Flow Cytometric Crossmatch vs. Virtual Crossmatch

Direct comparisons of virtual crossmatch predictions with physical FXM outcomes are shown in Tables 1a – 1c. Twenty-one labs submitted VXM predictions for serum 114 vs. donor V1 in Exchange 19. Of the 21 labs, 16 labs reported back physical T-cell FXM results and 15 labs reported physical B-cell FXM results for this patient-donor pair in Exchange 20 (Table 1a). All 16 labs predicting the T-cell FXM to be positive, reported the physical FXM as positive as well in the presence of strong anti-A2 (22603) reactivity

(Table 1b). Good agreement was also achieved between virtual B-cell predictions and the physical B-cell FXM, as 15 labs reported the B-cell FXM as positive in agreement with predictions (Table 1b). At the time of the paper challenge, a number of labs noted the positive prediction was due to the presence of class I DSA (A2), as there were no class II DSA reported against the cell.

**Table 1a. Summary of Virtual XM predictions vs. Physical Flow XM results - Direct comparison**

Exchange 019					Exchange 020				
Virtual Crossmatch - Serum 114 (Patient 2) vs. Donor V1					Physical Flow Crossmatch - Serum 117 vs. Cell 115				
Donor	Serum no.	#Labs	T-cell Prediction	B-cell Prediction	Cell	Serum no.	#Labs	T-cell Results	B-cell Results
V1	114	16	POS (16)	POS (15) Negative (1)	115	117	16	POS (16)	POS (15) NT (1)

**Table 1b. Direct comparison of Physical Flow Crossmatch results vs. Virtual Crossmatch results**

		T-cell Virtual XM (Exchange 19)			B-cell Virtual XM (Exchange 19)		
		+	-	Ø	+	-	Ø
Physical T-cell FXM (Exchange 20)	+	16			15		1
	-				1		
	Ø						
		+	16		15		1
		-			1		
		Ø					

+/- = positive/negative

Ø = uncertain/not typed

n = number of labs

The reporting of DSA and DSA strength was consistent across the 2 studies (Table 1c). In Exchange 19, anti-A2 (22937) reactivity was reported against the donor V2. In Exchange 20, anti-A2 reactivity was reported once

again against cell 117, with medium MFI = 22603. No class II DSA were reported against the donor in either study.

**Table 1c. Individual Physical Flow Crossmatch results vs. Virtual Crossmatch predictions - Direct Comparison**

Cell #115 HLA Genotype: A\*02:01-A\*11:01-B\*15:13-B\*38:02-C\*07:02-C\*08:01-DRB1\*15:02-DRB5\*01:01-DRB5\*01:08N-DQA1\*01:01-DQA1\*01:02-DQB1\*05:01-DQB1\*05:02-DPA1\*02:01-DPA1\*02:02-DPB1\*01:01-DPB1\*13:01

Exchange 019					Exchange 020				
Virtual Crossmatch - Serum 114 (Patient 2) vs. Donor V1					Physical Flow Crossmatch - Serum 117 vs. Cell 115				
Ctr	Virtual T-cell Prediction	Class I DSA(MFI)	Virtual B-cell Prediction	Class II DSA(MFI)	Ctr	T-Cell RESULT	Class I DSA(MFI)	B-Cell RESULT	Class II DSA(MFI)
54	Positive	A2(23432)	Positive	No Class II DSA	54	Positive	A*02:01(23,698)	Positive	No Class II DSA
230	Positive	A2(28282)	Negative	No Class II DSA	230	Positive	A2	Positive	No Class II DSA
774	Positive	A2(22727)	Positive	No Class II DSA	774	Positive	A2(22861.18)	Positive	No Class II DSA
792	Positive	A2(21062)	Positive	No Class II DSA	792	Positive	A2(22320)	Positive	No Class II DSA
1426	Positive	A2(20282) A2C(11519)	Positive	No Class II DSA	1426	Positive	A2(23380)	Positive	No Class II DSA
2400	Positive	A2(24613)	Positive	No Class II DSA	2400	Positive	A*02:01(23570)	Positive	No Class II DSA
3753	Positive	A2(22310)	Positive	No Class II DSA	3753	Positive	A2(21434)	Positive	No Class II DSA
3966	Positive	A2(21261)	Positive	DPA1*02(12590)	3966	Positive		Positive	
4661	Positive	A2(10911)	Positive	No Class II DSA	4661	Positive	A*02:01(10501)	Positive	No class II DSA
5214	Positive	A2(23569)	Positive	No Class II DSA	5214	Positive	A2(23495)	Positive	No Class II DSA
8001	Positive	A2(23191)	Positive	No Class II DSA	8001	Positive	A*02:01(24988)	Positive	No Class II DSA
8035	Positive	A2(25112)	Positive	No Class II DSA	8035	Positive	A*02:01(26,333)	Positive	No Class II DSA
8050	Positive	A2(22973)	Positive	No Class II DSA	8050	Positive	A2(22194)	Positive	No Class II DSA
8083	Positive	A2(28575)	Positive	No Class II DSA	8083	Positive	A*02:01(2872)	Positive	No Class II DSA
8096	Positive	A2(12645)	Positive	No Class II DSA	8096	Positive		NT	
8111	Positive	A2(21000)	Positive	No Class II DSA	8111	Positive	A2(20,000) B77(3200)	Positive	No Class II DSA

## Part 2

Class I and class II Luminex single antigen results for serum samples 117 - 120 are summarized in Tables 12 - 15 and individual results for each

participating laboratory are listed in Tables 16 – 23. In addition, individual cutoff values and sera pretreatment methods are shown on Table 32.

### Antibody Identification

**Serum 117:** This sample was previously examined as serum 114 in Exchange 19. A comparison of results from Exchange 19 and Exchange 20 showed the reporting of antibodies and antibody strength were consistent across the studies:

Exchange 19		Exchange 20		Exchange 19		Exchange 20	
Class I		Class I		Class II		Class II	
*** Serum 114 ***		*** Serum 117 ***		*** Serum 114 ***		*** Serum 117 ***	
Antigen	Median	Antigen	Median	Antigen	Median	Antigen	Median
A2	22937	A2	22603	DR4	18733	DR4	16935
A24	3146	A24	2782	DPw2	17565	DPw2	16828
A68	15556	A68	15756	DP18	15988	DP18	15137
A69	17626	A69	17065	DP28	15360	DP28	14522
B57	15453	B57	15214	DQ9	15222	DQ9	13889
B58	12893	B58	12858	DQ7	14929	DQ7	13975
A23	2300	A23	2328	DPw3	14188	DPw3	13721
A203	17435	A203	12285	DQ8	14008	DQ8	14160
A2403	1906	A2403	2103	DR11	13550	DR11	13619

A single DSA (A2), with MFI = 22603, was detected against cell 115 in this sample. Strong class II DSA were detected against cell 116, with labs reporting anti-DQ7 (13975) and DP4 (DP402) (15854) reactivity.

**Serum 118:** Anti-B60 (6251), -B7 (12177), -A3 (2775), -B42 (4480), -B55 (3174), -B61 (3538), and -B67 (4713) reactivity was detected in this sample by > 90% of labs. Additional reactivity to a number of B7C specificities was also detected. Class II reactivity was also detected in this sample, with labs reporting reactivity to DQ6 (9529), DR15 (6652), DR16 (3761), and DR51 (9702) in complete consensus.

#### Genotypes of cells provided by UCLA

**Cell 115 (Filipino)** - A\*02:01-A\*11:01-B\*15:13-B\*38:02-C\*07:02-C\*08:01-DRB1\*15:02-DRB5\*01:01-DRB5\*01:08N-DQA1\*01:01-DQA1\*01:02-DQB1\*05:01-DQB1\*05:02-DPA1\*02:01-DPA1\*02:02-DPB1\*01:01-DPB1\*13:01

**Cell 116 (Black)** - A\*03:01-A\*30:01-B\*41:02-B\*42:02-C\*17:01-DRB1\*08:04-DRB1\*15:03-DRB5\*01:01-DQA1\*01:02:01G-DQA1\*05:01:01G-DQB1\*03:01-DQB1\*06:02-DPB1\*04:02:01G-DPB1\*10:01

Weak anti-A11 (A1101) (1826) and -Cw7 (1889) reactivity, along with anti-DR15 (6652) and -DR51 (9702) reactivity was detected against cell 115. Multiple DSA were also reported against cell 116, with labs reporting anti-A3 (2775), -B42 (4480), -Cw17 (4831), -DQ6 (9529), -DR15 (6652), and -DR51 (9702) reactivity.

**Serum 119:** Strong anti-B57 (18251) and -B58 (15165) reactivity was detected in this cell, along with anti-A2 (6375) reactivity. In addition, reactivity to a number of 10C specificities, including A25 (13547), A26 (7855), A32 (5962), A34 (3416), and A43 (4751) was reported by > 90% of labs. Weak class II reactivity was also detected in this sample, with labs reporting anti-DQ7 (4811), -DQ8 (4422), -DQ9 (4559), and -DR7 (5497) reactivity in complete consensus.

Anti-A2 (6375) and -A11 (2726) reactivity was reported against cell 115. Against cell 116, only a single DSA (DQ7) was reported, with MFI = 4811.

**Serum 120:** Strong reactivity to a number of class I specificities was detected in this sample, including reactivity to B13 (19630), B41 (20606), B44 (16931), B45 (18810), B47 (18245), B48 (19080), B49 (20033), and B50 (19928). Each were reported by 100% of labs. The sample was reported as negative for class II.

No DSA were detected against cell 115 in this sample. By contrast, strong anti-B41 (20606), -Cw17 (11151), and -B42 (2500) reactivity was detected against cell 116.

#### Conclusion:

Good agreement was achieved for all 4 serum samples in the detection of class I and class II antibodies. MFI values for peak DSA ranged from 12177 to 23302 for class I antibodies and 5497 to 16828 for class II antibodies.

## Part 3

Flow cytometric crossmatch results for cell 115 and cell 116 against sera sample nos. 117 - 120 are summarized in Table 2. Individual results

for each laboratory, along with reported class I and class II DSA for each sera, are listed in tables 4 - 11.

### Flow Cytometric Crossmatch

**Cell 115.** For cell 115, 7 out of 8 T/B FXM achieved  $\geq 80\%$  agreement among labs. Among the FXM in which  $< 2$  discrepancies were observed, reported class I and/or class II DSA MFI were  $> 6000$ . Against cell 120, no agreement was achieved for the T-cell FXM. Interestingly, 13 labs reported it as negative, while 4 labs reported it as positive, and 2 reported borderline results despite the absence of class I DSA.

**Cell 116.** For cell 116, 6 out of 8 T/B FXM achieved  $\geq 80\%$  agreement. Among them, 5 were reported as positive in the presence of multiple class I and/or class II DSA. For serum 117, although there were no DSA detected against the cell, 4 labs reported the T-cell FXM as positive and 1 reported it as borderline. Finally for serum 120, weak anti-DQ7 (4811) reactivity resulted in only 79% of labs to report the B-cell FXM as positive.

**Table 2. Summary of Flow crossmatch results for Cell #115 - #116 vs. Serum #117 - #120**

Cell no.	Serum no.	#Labs	T-cell Results	B-cell Results	Cell no.	Serum no.	#Labs	T-cell Results	B-cell Results
115	117	22	POS(21) NT(1)	POS(18) NEG(1) NT(3)	116	117	22	NEG(14) POS(4) Borderline(1) NT(3)	POS(18) NEG(1) NT(3)
115	118	22	POS(16) NEG(4) NT(2)	POS(19) NT(3)	116	118	22	POS(20) NEG(1) NT(1)	POS(19) NT(3)
115	119	22	POS(21) NT(1)	POS(18) NEG(1) NT(3)	116	119	22	NEG(20) POS(1) NT(1)	POS(15) Borderline(1) NEG(3) NT(3)
115	120	22	NEG(13) POS(4) Borderline(2) NT(3)	NEG(17) POS(1) Borderline(1) NT(3)	116	120	22	POS(21) NT(1)	POS(18) NEG(1) NT(3)

indicates consensus  $< 80\%$

### Conclusion:

For the T-cell FXM, 6 out of 8 were reported with  $\geq 80\%$  agreement. The presence of multiple or strong class I DSA (MFI  $> 20000$ ) were present in the case of the positive crossmatches. For cell 115 vs. serum 120 and cell 116 vs. serum 117,  $< 80\%$  of labs reported the FXM as negative. The remaining labs reported the FXM as either positive or borderline despite the absence of class I DSA.

For the B-cell FXM, 7 out of 8 were reported with  $\geq 80\%$  agreement. The presence of strong (MFI  $> 9000$ ) class I and/or class II DSA were reported in the case of the positive B-cell FXM. For the remaining B-cell FXM, cell 116 vs. serum 119, no agreement was achieved. The weakness of the DSA (DQ7) present resulted in 3 labs to report a negative FXM and 1 to report the FXM as borderline instead of positive.

## Part 4

Virtual crossmatch predictions for donor V1 - V4 against sera (patient) samples 119 and 120 are summarized in Table 3 and individual laboratory

predictions are listed in Tables 24 - 31. Fictional donor histories precede each patient-donor summary.

### Virtual Crossmatch Paper Challenge

For virtual **T-cell predictions** of the expected T-cell FXM, all 8 T-cell VXM achieved  $\geq 80\%$  agreement among labs. Among them, 7 out of 8 are predicted to be positive due to the presence of class I DSA with MFI > 6000.

For virtual **B-cell predictions** of the expected B-cell FXM, all 8 B-cell VXM achieved  $\geq 80\%$  agreement among labs. All but 1 VXM, was predicted to be positive due to the presence of class II and/or class I DSA with MFI > 6000.

**Table 3. Summary of Virtual Crossmatch Predictions (Serum #119 - #120 vs. Donors V1 - V4)**

Donor no.	Serum no.	#Labs	T-cell Prediction	B-cell Prediction	Predicted Risk Assessment	Donor no.	Serum no.	#Labs	T-cell Prediction	B-cell Prediction	Predicted Risk Assessment
V1	119	20	POS(20)	POS(20)	Unacceptable(20)	V2	119	21	POS(20)	POS(20)	Unacceptable(20)
V1	120	20	POS(20)	POS(19) NT(1)	Unacceptable(20)	V2	120	21	NEG(20)	NEG(20)	Acceptable(20)
Donor no.	Serum no.	#Labs	T-cell Prediction	B-cell Prediction	Predicted Risk Assessment	Donor no.	Serum no.	#Labs	T-cell Prediction	B-cell Prediction	Predicted Risk Assessment
V3	119	20	Borderline(1)	Borderline(1)	Unacceptable(19) Acceptable(1)	V4	119	21	POS(20)	POS(20)	Unacceptable(20)
V3	120	20	POS(20)	POS(20)	Unacceptable(20)	V4	120	21	POS(20)	POS(20)	Unacceptable(20)

## DSA Identification

### Patient 1 (Serum 119)

**Patient's fictional case history:** This individual is a 35 year old male being evaluated for his first transplant. The patient's HLA type is A\*03:01-B\*07:02-B\*40:06-C\*07:02-DRB1\*15:01-DRB1\*15:02-DRB5\*01:02-DQA1\*01:01-DQA1\*01:02-DQB1\*05:01-DQB1\*05:02-DPA1\*02:02-DPA1\*04:01-DPB1\*01:01-DRB1\*02:01.

Against **donor V1**, anti-A11 (2726), -A66 (6635), and -DQ7 (4811) reactivity was detected in serum 119. The presence of multiple DSA resulted in good agreement to be achieved among T/B-cell predictions, as 20 out of 20 labs predict the expected T-cell and B-cell FXM to be positive. Predicted renal transplant risk for this donor-patient pair, as a result, was assessed to be unacceptable.

For serum 119 against **donor V2**, good agreement was achieved in the reporting of anti-A2 (6375) and -B57 (18251) reactivity. However, agreement among labs in the reporting of class II DSA was < 80%, as 4 labs indicated no class II DSA were present while 13 labs reported weak anti-DR52 (2046) reactivity. T/B-cell virtual predictions were not affected by the discrepancies in class II DSA reporting, as all 20 labs predict the expected T/B-cell FXM to be positive due to class I DSA. Consequently, predicted transplanted risk assessment was reported as unacceptable by all 20 labs.

Against **donor V3**, anti-A26 (7855) and -DR7 (5497) reactivity was reported. Good agreement was achieved for virtual T/B-cell predictions for this donor-patient pair, as 19 labs predict the expected FXM for each to be positive. One lab predicts the T/B-cell FXM for this donor against serum 119 to be borderline, as the DSA (A26, DR7, DQA1\*02) it detected against donor V1 were each < 1600 MFI. For renal transplant risk, all but the 1 lab predicting borderline results, predict the risk to be unacceptable.

Anti-A2 (6375) and -DR7 (5497) reactivity was detected against **donor V4** in serum 113 by 20 out of 20 labs. The presence of class I/II DSA of moderate strength resulted in all 20 labs to predict the expected T/B-cell FXM to be positive. Consequently, predicted risk assessment for this donor-patient pair was reported as unacceptable in complete agreement.

#### Virtual Donors – HLA genotype

**Donor 1 (V1):** A\*11:01-A\*66:01-B\*41:02-B\*44:02:01G-C\*05:01-C\*17:01:01G-DRB1\*08:01-DRB1\*13:03-DRB3\*01:01-DQA1\*04:01:01G-DQA1\*05:01:01G-DQB1\*03:01-DQB1\*04:02-DPA1\*01:03:01G-DPB1\*04:01-DPB1\*06:01

**Donor 2 (V2):** A\*02:01-A\*03:01-B\*35:03-B\*57:03-C\*04:01-C\*07:01-DRB1\*13:02-DRB3\*03:01-DQA1\*01:02-DQB1\*06:04-DPA1\*01:05-DPB1\*04:01

**Donor 3 (V3):** A\*26:01-A\*30:01-B\*13:02-B\*38:01-C\*06:02-C\*12:03-DRB1\*07:01-DRB4\*01:01-DRB4\*01:03-DQA1\*02:01-DQB1\*02:02-DPA1\*02:01-DPB1\*11:01-DPB1\*17:01

**Donor 4 (V4):** A\*01:01-A\*02:01-B\*13:02-B\*52:01-C\*06:02-C\*12:02-DRB1\*07:01-DRB1\*15:02:01G -DRB4\*01:03-DRB5\*01:02-DQA1\*01:03-DQA1\*02:01-DQB1\*02:02-DQB1\*06:01-DPA1\*01:03-DPA1\*02:01-DPB1\*04:01-DPB1\*17:01

## Patient 2 (Serum 120)

**Patient's fictional case history:** This individual is a 50 year old male being evaluated for his first transplant. The patient's HLA type is A\*23:01-A\*24:02-B\*14:02-B\*35:01-C\*07:02-C\*08:02-DRB1\*04:02-DRB1\*04:05-DRB4\*01:03-DQA1\*03:01-DQA1\*03:03-DQB1\*03:02-DPA1\*01:03-DPA1\*02:01-DPB1\*17:01-DPB1\*104:01

Against **donor V1**, strong anti-B41 (20606), -B44 (16931), and Cw17 (11151) reactivity was detected in serum 120. No class II DSA were detected. The presence of these strong antibodies resulted in 100% of labs to predict the expected T/B-cell FXM outcome to be positive for this donor-patient pair. In turn, predicted renal transplant risk was assessed as unacceptable by all 20 labs.

For sample 114 against **donor V2**, neither class I or class II DSA were detected by any lab. As result, all 20 labs predict the expected T/B-cell FXM outcome to be negative. Renal transplant risk was predicted to be acceptable by all 20 labs for this donor-patient pair.

Strong anti-B13 (19630) reactivity was reported against **donor V3** in this sample. No class II DSA were detected. Due to the strength of this class I antibody, all 20 labs predict the expected T/B-cell FXM outcome to be positive. Renal transplant risk, was in turn, predicted to be unacceptable by all 20 labs as well.

Against **donor V4**, a single DSA (B13) of 19630 MFI was reported. All 20 labs predict the T/B-cell FXM outcome to be positive for this donor-patient pair as a result of the strong DSA present. Good agreement (100%) was also achieved for renal transplant risk assessment, with labs predicting the risk of transplant as unacceptable.

## Conclusion

Good agreement ( $\geq 80\%$ ) was achieved for all 16 T/B-cell virtual cross-match predictions. For all but 1 of the 16 VXM, immune dominate class I/II DSA of  $> 6300$  MFI were present. This in turn, resulted in labs to predict

the expected T/B-cell FXM to be positive and to predict the expected renal transplant risk to be unacceptable.

**NEXT MAILING DATE: March 24, 2021**

*Arlene Locke, David Gjertson, Qiuheheng Zhang, and Elaine F. Reed*

# **Flow Cytometric Crossmatch**

Cell #115 HLA Genotype: A\*02:01-A\*11:01-B\*15:13-B\*38:02-C\*07:02-C\*08:01-DRB1\*15:02-DRB5\*01:01-DRB5\*01:08N-DQA1\*01:01-DQA1\*01:02-DQB1\*05:01-DQB1\*05:02-DPA1\*02:01-DPA1\*02:02- DPB1\*01:01-DPB1\*13:01

**Table 4. Individual Flow crossmatch results and DSA reported for Cell #115 vs. Serum #117**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
54	117	61	446			Positive	A*02:01(23,698)	91	370			Positive	No Class II DSA	75	137	YES
230	117	3.5	31.5			Positive	A2	4.5	60.2			Positive	No Class II DSA			YES
615	117	314	742			Positive Strong	A*02:01(22827)	336	692			Positive Strong	No Class II DSA	249	238	YES
774	117	≥ 50	345			Positive	A2(22861.18)	≥ 120	183.5			Positive	No Class II DSA	236	425.5	NO
792	117	52	375			Positive	A2(22320)	106	321			Positive	No Class II DSA	241	282	YES
1160	117	65	526			Positive	A2(19738)	70	444			Positive	None	180	206	YES
1426	117	50	328			Positive	A2(23380)	92	314			Positive	No Class II DSA	347	322	YES
													No Class II DSA. Positive reactivity due to Class I.			
2400	117	18	283			Positive	A*02:01(23570)	24	248			Positive		85	26	YES
3135	117	1,2	4861	3,2		Positive						NT		1630		NO
3224	117	70	388			Positive	A2(24954)	140	281			Positive	No Class II DSA	167	166	YES
3753	117	50	395			Positive	A2(21434)	100	338			Positive	No Class II DSA	208	225	YES
3966	117	20	396			Positive		50	315			Positive		169	258	NO
4345	117					Positive						Negative				NO
4661	117	10	408			Positive	A*02:01(10501)	10	403			Positive	No class II DSA	182	204	YES
5214	117	18	126		337232	Positive	A2(23495)	27	101	192880		Positive	No Class II DSA	253	263	YES
8001	117	50	457			Positive	A*02:01(24988)	100	370			Positive	No Class II DSA	207	273	YES
8035	117	>48	357			Positive	A*02:01(26,333)	>90	369			Positive	No Class II DSA	158	160	YES
8050	117	50	420		35053	Positive	A2(22194)	120	426	77702		Positive	No Class II DSA	40	104	YES
8062	117					NT						NT				YES
8083	117	70	295			Positive	A*02:01(2872)	140	219			Positive	No Class II DSA	191	261	YES
8096	117	5	253.45			Positive						NT		13.1		NO
8111	117	37	298			Positive	A2(20,000) B77(3200)	69	273			Positive	No Class II DSA	225	225	NO

**Table 5. Individual Flow crossmatch results and DSA reported for Cell #115 vs. Serum #118**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
54	118	61	107			Positive	A*11:01(1,639); C*07:02(1,256)	91	288			Positive	DRB5*01:01(9,781); DRB1*15:02(7,240)	75	137	YES
230	118	3.5	0.6			Negative		4.5	34.8			Positive	DR15, DR51			YES
615	118	314	384			Positive Moderate	A*11:01(1364); C*07:02(1930)	336	562			Positive	DRB1*15:02 (7075); DRB5*01:01 (10223)	249	238	YES
774	118	≥ 50	55			Negative		≥ 120	162.5			Positive	DRB1*15:02 (7083.44), DRB5*01 (10224.73)	236	425.5	NO
792	118	52	105			Positive	A11(1934), Cw7(1548)	106	286			Positive	DR51(9438), DR15(6342)	241	282	YES
1160	118	65	171			Positive	A11(719)	70	365			Positive	DR15(4720); DR51(7272)	180	206	YES
1426	118	50	29			Negative		92	253			Positive	DR15(6101), DR51(7991)	347	322	YES
2400	118	18	40			Positive	A*11:01(1116), C*07(1422)	24	135			Positive	DRB1*15*02(6767), DRB5*01:01(10328)	85	26	YES
3135	118	1.2	1651	1,1		Negative						NT		1630		NO
3224	118	70	39			Positive	A11(2457), Cw7(2037)	140	199			Positive	DR15(7342), DR51(9881)	167	166	YES
3753	118	50	90			Positive	A11(1351)	100	274			Positive	DR15(5551), DR51(8025)	208	225	YES
3966	118	20	96			Positive		50	261			Positive		169	258	NO
4345	118					Positive						Positive				NO
4661	118	10	71			Positive	A*11:01(667)	10	181			Positive	DRB1*15:02(3633), DRB5*01:01(6828)	182	204	YES
5214	118	18	38		9151	Positive	A11(2302) C7(2184)	27	86		105157	Positive	DR15(9429) DRB5*01:01(13040)	253	263	YES
8001	118	50	162			Positive	A*11:01(1835) C*07:02(1848)	100	327			Positive	DRB1*15:02(6306) DRB5*01:01(9083)	207	273	YES
8035	118	>48	92			NT	A*11:01(1500), C*07:02(1929) Note:possible 1C and 8C CREG reactivity	>90	267			Positive	DRB1*15:02(9879), DRB5*01:01(12803)	158	160	YES
8050	118	50	117		1118	Positive	A11(1384) Cw7(1312)	120	378		45017	Positive	DR15(6753) DR51(9654)	40	104	YES
8062	118					NT						NT				YES
8083	118	70	154			Positive	A*11:01(1730) C*07:02(1661)	140	298			Positive	DRB1*15:02(6715) DRB5*01:01(9749)	191	261	YES
8096	118	5	5.84			Positive						NT		13.1		NO
8111	118	37	57			Positive	Cw7(1500) A11(1000)	69	216			Positive	DR51(9000) DR15(6000)	225	225	NO

**Table 6. Individual Flow crossmatch results and DSA reported for Cell #115 vs. Serum #119**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
54	119	61	231			Positive	A*02:01(7,605); A*11:01(3,123)	91	171				Positive due to Class I's DSA	75	137	YES
230	119	3.5	6			Positive	A2, A11	4.5	17.3			Positive	No class II DSA			YES
615	119	314	525			Positive	A*02:01(6177); A*11:01(2614)	336	479			Positive	DPB1*01:01 (1098)	249	238	YES
774	119	≥ 50	150			Positive	A2(6808.82), A11(2198.23)	≥ 120	19.5			Negative	No Class II DSA	236	425.5	NO
792	119	52	209			Positive	A2(6028), A11(3525)	106	159			Positive	No class II DSA	241	282	YES
1160	119	65	296			Positive	A2(4675); A11(1789)	70	217			Positive	No class II DSA	180	206	YES
1426	119	50	141			Positive	A11(1422), A2(4821)	92	125			Positive	No class II DSA	347	322	YES
2400	119	18	105			Positive	A*02:01(6549), A*11:01(2873)	24	38			Positive	No Class II DSA. Positive reactivity due to Class I.	85	26	YES
3135	119	1,2	2013	1,3		Positive						NT		1630		NO
3224	119	70	171			Positive	A2(9010), A11(5022)	140	56			Positive	No class II DSA	167	166	YES
3753	119	50	193			Positive	A2(6118), A11(2726)	100	133			Positive	No class II DSA	208	225	YES
3966	119	20	189			Positive		50	148			Positive		169	258	NO
4345	119					Positive						Positive				NO
4661	119	10	193			Positive	A*02:01(2361), A*11:01(1924)	10	178			Positive	No class II DSA	182	204	YES
5214	119	18	70		38205	Positive	A2(10168) A11(3991)	27	48		21698	Positive	No class II DSA	253	263	YES
8001	119	50	259			Positive	A*02:01(7634) A*11:01(3117) B*15:13(574)	100	195			Positive	DRB1*15:02(6306) DPB1*01:01(550)	207	273	YES
8035	119	>48	215			Positive	A*02:01(6905), A*11:01(1971) B*15:13(879)	>90	209			Positive	No class II DSA	158	160	YES
8050	119	50	231		4086	Positive	A2(5906) A11(2449)	120	144		3146	Positive	No class II DSA	40	104	YES
8062	119				NT							NT				YES
8083	119	70	153			Positive	A*02:01(8030) A*11:01(3183)	140	114			Positive	No class II DSA	191	261	YES
8096	119	5	25.79			Positive						NT		13.1		NO
8111	119	37	126			Positive	A2(5000) A11(1800)	69	92			Positive	No class II DSA	225	225	NO

**Table 7. Individual Flow crossmatch results and DSA reported for Cell #115 vs. Serum #120**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
54	120	61	35			Negative	No Class I DSA	91	24			Negative	No Class II DSA	75	137	YES
230	120	3.5	0.1			Negative	No Class I DSA	4.5	0.2			Negative	No Class II DSA			YES
615	120	314	291			Negative	No Class I DSA	336	269			Negative	No Class II DSA	249	238	YES
774	120	≥ 50	36			Negative	No Class I DSA	≥ 120	37.5			Negative	No Class II DSA	236	425.5	NO
792	120	52	76			NT	B38(785)	106	32			Negative	No Class II DSA	241	282	YES
1160	120	65	89			Borderline	No Class I DSA	70	37			Negative	No Class II DSA	180	206	YES
1426	120	50	-29			Negative	No Class I DSA	92	-15			Negative	No Class II DSA	347	322	YES
2400	120	18	15			Negative	No Class I DSA	24	13			Negative	No Class II DSA	85	26	YES
3135	120	1,2	1668	1,0		Negative						NT		1630		NO
3224	120	70				Borderline	B38(1323)	140				Negative	No Class II DSA	167	166	YES
3753	120	50	41			Negative	No Class I DSA	100	23			Negative	No Class II DSA	208	225	YES
3966	120	20	15			Negative		50	19			Negative		169	258	NO
4345	120					Negative						Negative				NO
4661	120	10	22			Positive	No Class I DSA	10	4			Negative	No class II DSA	182	204	YES
							Weak B38:01(1141) Allele of B38, but not the targeted B38:02. B38:02 not on Single Antigen panel.									
5214	120	18	7		1032	Negative		27	2		361	Negative	No Class II DSA	253	263	YES
8001	120	50	77			Positive	C*08:01(739)	100	42			Negative	No Class II DSA	207	273	YES
							NONE; possible 5C and 8C CREG reactivity						NONE; possible 5C and 8C CREG reactivity			
8035	120	>48	73			NT		>90	92			Borderline		158	160	YES
8050	120	50	35		440	Negative	No Class I DSA	120	0		1929	Negative	No Class II DSA	40	104	YES
8062	120					NT						NT				YES
8083	120	70	155			Positive	B38(1100)	140	184			Positive	No Class II DSA	191	261	YES
8096	120	5	6.89			Positive						NT		13.1		NO
8111	120	37	28			Negative	No Class I DSA	69	24			Negative	No Class II DSA	225	225	NO

**Table 8. Individual Flow crossmatch results and DSA reported for Cell #116 vs. Serum #117**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
54	117	61	26			Negative	No Class I DSA	91	355			Positive	DQA1*05:01/ DQB1*03:01(17,838)	73	137	YES
230	117	6.5	0.5			Negative	No Class I DSA	8.5	64.7			Positive	DQ7, DP0402			YES
													DQB1*03:01 DQA1*05:03 (12740); DPB1*04:02(10888)	227	277	YES
615	117	292	269			Negative	No Class I DSA	375	655			Positive	DQB1*03:01(16846), DPB1*04:02(17049)	240	390.5	NO
774	117	≥ 50	11			Negative	No Class I DSA	≥ 120	255.5			Positive	DQ7(14756)	212	283	YES
792	117	52	88			NT		106	422				DP4(11406); DQ7(10462)	167	258	YES
1160	117	65	40			Negative	No Class I DSA	70	395			Positive	DP4(15008), DQ8(11209)	302.5	336	YES
1426	117	50	-1.5			Negative	No Class I DSA	92	381			Positive	DQB1*03:01(12413), DPB1*04:02(15595)	62	60	YES
2400	117	18	NT			NT		24	188			Positive	NT	1911		NO
3135	117	1,2	1924	1,0		Negative							DPB1*05:01(17532), DQ7(18866), DPB1*04:02(17532)	167	166	YES
													DQ7(13194), DP402(16825)	203	253	YES
3224	117	70				Negative	No Class I DSA	140	323			Positive		183	329	NO
3753	117	50	37			Negative	No Class I DSA	100	350			Positive				NO
3966	117	20	34			Borderline		50	305			Positive				
4345	117					Negative						Negative				
4661	117	10	1			Negative	No Class I DSA	10	196			Positive	DQB1*03:01(5652), DPB1*04:02(8413)	197	239	YES
5214	117	18	3		396	Negative	No Class I DSA	27	92		188917	Positive	DQ7(16,025), DPB4:02(19599)	255	272	YES
8001	117	50	65			Positive	A*03:01(479)	100	347			Positive	DQB1*03:01(17329) DPB1*04:02(16580)	198	309	YES
													DQ7(16,025), DPB1*04:02(19,934), DP105(15,792)	158	168	YES
8035	117	>48	26			Negative	No Class I DSA	>90	472			Positive	DQ7(13077)	34	176	YES
8050	117	50	39		430	Negative	No Class I DSA	120	240		21253	Positive	DPB1*04:02(16991)			
8062	117					NT						NT				
8083	117	70	251			Positive	No Class I DSA	140	376			Positive	DQB1*03:01(16324) DPB1*04:02(15447)	318	398	YES
8096	117	5	5.95			Positive						NT		14.59		NO
8111	117	37	38			Positive	No Class I DSA	69	336			Positive	DQ7(7000) DPB1*04:02(6800)	239	236	NO

**Table 9. Individual Flow crossmatch results and DSA reported for Cell #116 vs. Serum #118**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
54	118	61	169			Positive	A*03:01(3,394); B*42:02(3,240); C*17:01(4,174)	91	297			Positive	DQA1*01:02/ DQB1*06:02(6,382); DRB5*01:01(9,781) DRB1*15:03(6,700)	73	137	YES
230	118	6.5	9.5			Positive	A3, B42	8.5	39.1			Positive	DR15, DQ6			YES
615	118	292	440			Positive Moderate	A*03:01(3718); B*42:01(5289); C*17:01(5334)	375	586			Positive	DRB1*15:03(6533); DRB5*01:01(10223); DQB1*06:02 DQA1*01:02(4841)	227	277	YES
774	118	≥ 50	133			Positive	B42(4519)	≥ 120	214.5			Positive	DRB5*01:01(10225), DRB1*15:03(6754), DQB1*06:02(6537)	240	390.5	NO
792	118	52	184			Positive	B42(4465), Cw17(4349), A3(3244)	106	318			Positive	DR51(9438), DR6(9078), DR15(6342)	212	283	YES
1160	118	65	226			Positive	A3(1633); Cw17(2888); B*42:01(2583)	70	305			Positive	DR15(4505); DR51(7272); DQ6(3356)	167	258	YES
1426	118	50	178.5			Positive	A3(2394), B42(4127), Cw7(3643)	92	308			Positive	DQ6(6916), DQ8(2357), DR15(5554), DR51(7737)	302.5	336	YES
2400	118	18	67			Positive	A*03:01(2916), B*42(4097), C*17(4070)	24	122			Positive	DRB1*15:03(6138), DRB5*01:01(10328), DQB1*06:02(5586)	62	60	YES
3135	118	1,2	2107	1,1		Negative						NT		1911		NO
3224	118	70	79			Positive	A3(4346), B42(6067), Cw17(6360)	140	211			Positive	DR15(7342), DR51(9881), DQ6(7066)	167	166	YES
3753	118	50	156			Positive	A3(2775), B42(4204), Cw17(5570)	100	264			Positive	DR15(5551), DR51(8025), DQ6(6681)	203	253	YES
3966	118	20	153			Positive		50	234			Positive		183	329	NO
4345	118					Positive						Positive				NO
4661	118	10	109			Positive	A*03:01(1146), B*42:01(921), C*17:01(589)	10	205			Positive	DRB1*15:03(3310), DRB5*01:01(6828), DQB1*06:02(3035)	197	239	YES
5214	118	18	52		18986	Positive	A3(4869), C17(7176)	27	73		87274	Positive	DQ6(7485), DR15(8747), DRB5*01:01(13040)	255	272	YES
8001	118	50	253			Positive	A*03:01(3945) C*17:01(5286)	100	277			Positive	DRB5*01:01(9083) DRB1*15:03(5714) DQB1*06:02(6166)	198	309	YES

**Table 9. Individual Flow crossmatch results and DSA reported for Cell #116 vs. Serum #118**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
8035	118	>48	176			Positive	A*03:01(2514), B*42:02(6064), C*17:01(5803)	>90	326			Positive	DRB1*15:03(9219), DRB5*01:01(12,803), DQB1*06:02(7707)	158	168	YES
8050	118	50	193		2478	Positive	A3(2632) B42(4480) Cw17(4107)	120	210		15110	Positive	DR15(6753) DR51(9654) DQ6(7406)	34	176	YES
8062	118					NT						NT				YES
8083	118	70	242			Positive	A*03:01(3731) C*17:01(5489)	140	256			Positive	DRB1*15:03(6590) DRB5*01:01(9749) DQB1*06:02(6972)	318	398	YES
8096	118	5	32.81			Positive						NT		14.59		NO
8111	118	37	87			Positive	B42(4000) C*17(4000) A3(2500)	69	250			Positive	DR51(9000) DQ6(4000) DR15(6000)	239	236	NO

**Table 10. Individual Flow crossmatch results and DSA reported for Cell #116 vs. Serum #119**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
54	119	61	-15			Negative	No Class I DSA	91	99			Positive	DQA1*05:01/ DQB1*03:01(6,417)	73	137	YES
230	119	6.5	0.1			Negative	No Class I DSA	8.5	12.1			Positive	DQ7			YES
615	119	292	246			Negative	No Class I DSA	375	380			Positive	DQB1*03:01 DQA1*05:03(7552)	227	277	YES
774	119	≥ 50	-2			Negative	No Class I DSA	≥ 120	19.5			Negative	DQB1*03:01(3920.45)	240	390.5	NO
792	119	52	44			Negative	No Class I DSA	106	170			Positive	DQ7(4937)	212	283	YES
1160	119	65	10			Negative	No Class I DSA	70	119			Positive	DQ7(3306)	167	258	YES
1426	119	50	-25.5			Negative	No Class I DSA	92	102			Positive	DQ8(3573)	302.5	336	YES
2400	119	18	14			Negative	No Class I DSA	24	31			Positive	DQB1*03:01(3008)	62	60	YES
3135	119	1,2	1825	0,9		Negative						NT		1911		NO
3224	119	70				Negative	No Class I DSA	140	8			Positive	DQ7 6452	167	166	YES
3753	119	50	11			Negative	No Class I DSA	100	89			Negative	DQ7(4962)	203	253	YES
3966	119	20	17			Negative		50	68			Borderline		183	329	NO
4345	119					Negative						Positive				NO
4661	119	10	0			Negative	No class I DSA	10	32			Positive	DQB1*03:01(2058)	197	239	YES
5214	119	18	0		0	Negative	No Class I DSA	27	26		9777	Positive	DQ7(5430)	255	272	YES
8001	119	50	28			Negative	A*30:01(740)	100	138			Positive	DQB1*03:01(5769)	198	309	YES
8035	119	>48	10			Negative	No Class I DSA	>90	119			Positive	DQ7(6560)	158	168	YES
8050	119	50	18		339	Negative	No Class I DSA	120	23		1802	Negative	DQ7(4685)	34	176	YES
8062	119					NT						NT				YES
8083	119	70	264			Positive	No Class I DSA	140	178			Positive	DQB1*03:01(5480)	318	398	YES
8096	119	5	0.13			Negative						NT		14.59		NO
8111	119	37	25			Negative	No Class I DSA	69	72			Positive	DQ7(5000)	239	236	NO

**Table 11. Individual Flow crossmatch results and DSA reported for Cell #116 vs. Serum #120**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
54	120	61	404			Positive	B*41:02(15,949); C*17:01(8,053)	91	350			Positive	No Class II DSA	73	137	YES
230	120	6.5	36.4			Positive	B41	8.5	44			Positive	No Class II DSA			YES
615	120	292	659			Positive	B*41:01(19611); B*42:01(2019); C*17:01(9519)	375	649			Positive	No Class II DSA	227	277	YES
774	120	≥ 50	310			Positive	B41(20935.45), B42(2500.39)	≥ 120	229.5			Positive	No Class II DSA	240	390.5	NO
792	120	52	361			Positive	B41(18956)	106	332			Positive	No DSA Detected	212	283	YES
1160	120	65	415			Positive	B*41:01(17797); B*42:01(1658); Cw17(8550)	70	322			Positive	No Class II DSA	167	258	YES
1426	120	50	346.5			Positive	Cw17(9052), B41(19272), B42(1596)	92	309			Positive	No Class II DSA	302.5	336	YES
2400	120	18	195			Positive	B*41(23585), B*42(3450), C*17(12860)	24	164			Positive	No Class II DSA Positive reactivity due to Class I DSA.	62	60	YES
3135	120	1.2	3929	2.0		Positive						NT		1911		NO
3224	120	70	320			Positive	B41(22211), B42(3420), Cw17(12526)	140	284			Positive	No Class II DSA	167	166	YES
3753	120	50	339			Positive	B41(19493), B42(1812), Cw17(12946)	100	357			Positive	No Class II DSA	203	253	YES
3966	120	20	304			Positive		50	267			Positive		183	329	NO
4345	120					Positive						Negative				NO
4661	120	10	340			Positive	B*41:01(9266), C*17:01(2519)	10	365			Positive	No class II DSA	197	239	YES
5214	120	18	105		167832	Positive	C17(12667)	27	79	112767		Positive	No Class II DSA	255	272	YES
8001	120	50	452			Positive	C*17:01(12600)	100	298			Positive	No Class II DSA	198	309	YES
8035	120	>48	374			Positive	B*41:02(22,774), B*42:02(1365), C*17:01(11,652)	>90	407			Positive	No class II DSA; no BRB1*08:04 bead available	158	168	YES
8050	120	50	407		28242	Positive	B41(20462) B42(1846) Cw17(8452)	120	296	40178	Positive	No Class II DSA		34	176	YES
8062	120					NT						NT				YES
8083	120	70	361			Positive	Possible DSA to B*41:02(no single antigen bead to detect). B42(2925) C*17:01(12159)	140	282			Positive	No Class II DSA	318	398	YES

**Table 11. Individual Flow crossmatch results and DSA reported for Cell #116 vs. Serum #120**

Ctr	Serum no	T-Cell Pos cutoff	T Cell MCS	RATIO	MESF	T-Cell RESULT	Class I DSA(MFI)	B-Cell Pos cutoff	B-cell MCS	RATIO	MESF	B-Cell RESULT	Class II DSA(MFI)	T-Cell NEG Control MC	B-Cell NEG Control MC	Pronase Treated
8096	120	5	216.23			Positive						NT		14.59		NO
8111	120	37	131			Positive	C*17(10,000) B41(20,000) B42(2000)	69	130			Positive	No Class II DSA	239	236	NO

# **Luminex Single Antigen**

**Table 12. Summary of Single Antigen results for Serum #117**

Class I								
*** Serum 117 ***								
18 typing Labs								
Antigen	No.Labs	Consensus	Median	Mean	Std Dev	Min	Max	
A2	18	100%	22603	21410	4714	9088	27900	
A24	18	100%	2782	3641	1864	1109	6621	
A68	18	100%	15756	15189	4542	5397	20870	
A69	18	100%	17065	16388	5326	3626	22063	
B57	18	100%	15214	13999	4625	2848	19703	
B58	18	100%	12858	11839	4053	1708	17002	
A23	17	94%	2328	2560	1155	500	4161	
A203	4	22%	12285	14175	6549	7301	24830	
A2403	4	22%	2103	2899	1995	1109	6282	

**Blue** = DSA against cell #115 only

**Gold** = DSA against cell #116 only

**Green** = DSA against cell #115 and #116

Class II								
*** Serum 117 ***								
18 typing Labs								
Antigen	No.Labs	Consensus	Median	Mean	Std Dev	Min	Max	
DPw2	18	100%	16828	15461	4668	5134	21306	
DPw3	18	100%	13721	12409	3790	4216	17579	
DPw6	18	100%	12993	11791	3451	4364	15813	
DQ7	18	100%	13975	13161	4672	3525	20200	
DQ8	18	100%	14160	13048	4038	4535	18096	
DQ9	18	100%	13889	12798	4283	4048	19000	
DR11	18	100%	13619	12595	3393	5023	16702	
DR4	18	100%	16935	16455	3422	8293	23400	
DP14	17	94%	12299	11298	3291	4041	15875	
DP17	17	94%	12479	11490	3681	3525	16728	
DP18	17	94%	15137	14044	3917	5163	18663	
DP28	17	94%	14522	13536	3823	4819	18100	
DP9	17	94%	14010	12764	3946	3836	18074	
DQ4	17	94%	3477	3551	1107	1530	5342	
DP10	15	83%	12970	12370	2765	4320	16219	
DP20	15	83%	14093	13437	2875	5241	17293	
DP402	11	61%	16991	15479	4503	5741	19934	
DPw4	8	44%	14716	12576	4004	5741	17049	
DQA1*03	3	16%	7680	7719	3191	3831	11648	
DQA1*06	3	16%	6859	10017	7166	3257	19935	
DQA1*05	2	11%	12863	12863	6089	6774	18952	
DPA1*01	1	5%	17089	17089	-	17089	17089	
DPA1*03	1	5%	11985	11985	-	11985	11985	
DPA1*04	1	5%	15283	15283	-	15283	15283	
DPw1	1	5%	4715	4715	-	4715	4715	
DPw5	1	5%	6589	6589	-	6589	6589	
DQ3	1	5%	4535	4535	-	4535	4535	
DQA1*04	1	5%	4048	4048	-	4048	4048	
DR8	1	5%	603	603	-	603	603	

**Table 13. Summary of Single Antigen results for Serum #118**

Class I								
*** Serum 118 ***								
18 typing Labs								
Antigen	No.Labs	Consensus	Median	Mean	Std Dev	Min	Max	
B60	18	100%	6251	5797	2369	704	9215	
B7	18	100%	12177	11147	3975	2350	16058	
A3	17	94%	2775	2879	1230	555	4869	
B42	17	94%	4480	4382	1620	921	6909	
B55	17	94%	3174	3129	1114	719	4835	
B61	17	94%	3538	3352	1265	536	5057	
B67	17	94%	4713	4486	1637	824	6987	
B48	16	88%	5367	5289	1719	894	7809	
B13	15	83%	2503	2425	754	527	3660	
B27	15	83%	4714	4385	1885	804	6900	
B56	15	83%	2747	2679	1037	547	4532	
Cw17	14	77%	4831	4830	1573	1089	7176	
B81	13	72%	10509	11063	2009	7485	14541	
Cw18	12	66%	2688	2850	596	1931	4077	
Cw6	11	61%	2580	2732	602	1793	3850	
A11	10	55%	1826	1780	545	923	2639	
B54	10	55%	1761	1848	504	900	2763	
B73	10	55%	1969	1946	473	990	2751	
B82	10	55%	2000	1981	669	690	3145	
A80	9	50%	1770	1735	475	525	2424	
A36	8	44%	1190	1250	596	510	2237	
Cw7	8	44%	1889	1839	352	1312	2400	
A1	7	38%	1400	1373	618	510	2327	
B2708	7	38%	3856	4196	2693	937	8391	
B47	7	38%	1181	1158	374	552	1615	
B2705	6	33%	2636	3196	2265	759	6473	
Cw5	6	33%	1718	1740	398	1222	2300	
B8101	5	27%	3754	6474	5150	1129	13090	
A1101	4	22%	733	998	500	667	1860	
A1102	3	16%	1509	1504	780	547	2457	
B703	3	16%	1856	2031	819	1127	3110	
Cw15	3	16%	1949	1835	275	1457	2100	

Class II								
*** Serum 118 ***								
18 typing Labs								
Antigen	No.Labs	Consensus	Median	Mean	Std Dev	Min	Max	
DQ6	18	100%	9529	8260	3187	1446	12800	
DR15	18	100%	6652	6422	2203	1683	9539	
DR16	18	100%	3761	3672	1253	1157	5590	
DR51	18	100%	9702	9276	2611	3608	13600	
DQ8	17	94%	3438	3072	1344	511	5099	
DQ9	16	88%	3159	2967	1156	670	4594	
DP401	4	22%	1202	1120	194	791	1289	
DQA1*01	3	16%	10072	8508	4483	2405	13047	
DQA1*03	3	16%	3085	2968	1868	625	5196	
DPA1*04	1	5%	1087	1087	-	1087	1087	
DQ3	1	5%	728	728	-	728	728	
DQA1*02	1	5%	728	728	-	728	728	
DQA1*04	1	5%	670	670	-	670	670	
DR3	1	5%	3438	3438	-	3438	3438	

**Blue** = DSA against cell #115 only

**Gold** = DSA against cell #116 only

**Green** = DSA against cell #115 and #116

**Table 14. Summary of Single Antigen results for Serum #119**

Class I								
*** Serum 119 ***								
18 typing Labs								
Antigen	No.Labs	Consensus	Median	Mean	Std Dev	Min	Max	
A2	18	100%	6375	6237	2154	1639	10122	
A25	18	100%	13547	12185	4045	2680	17775	
A26	18	100%	7855	7355	2440	1533	10828	
A32	18	100%	5962	5286	2031	649	7928	
A34	18	100%	3416	3252	1281	629	5186	
A43	18	100%	4751	4543	1664	992	7083	
B57	18	100%	18251	16520	4720	3854	21300	
B58	18	100%	15165	13755	4267	2275	18633	
A29	16	88%	2456	2454	774	1017	3790	
A31	16	88%	2372	2352	811	831	3969	
A33	16	88%	2632	2684	872	1072	4291	
A68	16	88%	2136	2314	945	560	3861	
A11	15	83%	2726	2872	1076	643	4554	
A74	15	83%	1929	1887	622	640	3031	
A66	14	77%	6635	6830	2111	2034	10500	
A69	14	77%	1880	1968	820	573	3452	
B63	14	77%	2435	2306	722	738	3400	
A6601	5	27%	4599	6457	3946	2034	11899	
A6602	5	27%	1635	2334	1500	629	4259	
A1101	4	22%	2871	2594	1388	643	3991	
A1102	4	22%	3297	3131	2073	607	5325	
A203	4	22%	2366	3615	3100	860	8871	
B76	1	5%	991	991	-	991	991	
B77	1	5%	879	879	-	879	879	

Class II								
*** Serum 119 ***								
18 typing Labs								
Antigen	No.Labs	Consensus	Median	Mean	Std Dev	Min	Max	
DQ7	18	100%	4811	4552	1752	692	7100	
DQ8	18	100%	4422	4258	1467	965	6212	
DQ9	18	100%	4559	4161	1589	674	6400	
DR7	18	100%	5497	5170	1794	1254	8417	
DR9	15	83%	2208	2257	688	673	3400	
DR12	10	55%	1524	1456	319	725	1850	
DR52	9	50%	2046	2121	533	1257	3200	
DQA1*03	3	16%	5138	3997	2359	712	6142	
DQA1*05	3	16%	5585	4773	3055	692	8043	
DQA1*06	3	16%	5753	4857	3202	566	8254	
DQA1*02	2	11%	2255	2255	1290	965	3545	
DPA1*03	1	5%	965	965	-	965	965	
DPw5	1	5%	734	734	-	734	734	
DQ3	1	5%	965	965	-	965	965	
DQA1*04	1	5%	663	663	-	663	663	

**Blue** = DSA against cell #115 only

**Gold** = DSA against cell #116 only

**Green** = DSA against cell #115 and #116

**Table 15. Summary of Single Antigen results for Serum #120**

Class I								
*** Serum 120 ***								
18 typing Labs								
Antigen	No.Labs	Consensus	Median	Mean	Std Dev	Min	Max	
B13	18	100%	19630	18269	5487	2930	23900	
<b>B41</b>	18	100%	20606	18881	5199	4457	23700	
B44	18	100%	16931	15742	4233	4519	20300	
B45	18	100%	18810	17072	4948	3807	22015	
B47	18	100%	18245	17053	4045	4781	21159	
B48	18	100%	19080	16655	6216	753	21637	
B49	18	100%	20033	18209	5560	3307	23900	
B50	18	100%	19928	18119	5022	4225	23000	
B4005	1	5%	21809	21809	-	21809	21809	
B60	18	100%	23302	22010	5326	6672	28288	
B61	18	100%	23058	21395	5291	6283	28100	
B7	18	100%	20799	19204	4609	6281	24100	
B73	18	100%	19061	16942	4823	3967	21827	
<b>Cw17</b>	18	100%	11151	9945	3664	1075	14200	
Cw2	18	100%	11954	10279	3859	1140	14212	
B27	15	83%	18119	16893	4609	5535	22100	
B62	14	77%	2474	2411	804	574	3400	
B67	14	77%	2687	2469	745	501	3292	
B81	14	77%	20270	19384	4533	4564	24000	
<b>B42</b>	13	72%	2500	2522	676	1564	3470	
A6602	11	61%	14127	13444	4231	4603	17990	
B55	9	50%	1971	1888	311	1414	2259	
A66	8	44%	12294	12151	4091	4603	17892	
B2708	7	38%	20225	16551	5268	7351	21772	
B72	7	38%	2013	1810	356	1128	2100	
Cw9	7	38%	1812	1786	387	1280	2328	
B2705	6	33%	15026	14127	4814	6422	19588	
B8101	5	27%	12438	13942	6849	4564	22049	
Cw10	5	27%	1541	1617	327	1149	2142	
B38	4	22%	1274	1226	167	959	1400	
B39	4	22%	1426	1394	177	1125	1600	
B703	3	16%	7898	7487	2661	4043	10522	

Class II								
*** Serum 120 ***								
18 typing Labs								
Antigen	No.Labs	Consensus	Median	Mean	Std Dev	Min	Max	
NEG	17	94%	1300	1300	-	1300	1300	
DP11	1	6%	1300	1300	-	1300	1300	

**Blue** = DSA against cell #115 only

**Gold** = DSA against cell #116 only

**Green** = DSA against cell #115 and #116

**Table 16a. Individual laboratory results for Serum #117 - class I by One Lambda Single Antigen**

Ctr	**** Serum 117 ****										
	A2	A24	A68	A69	B57	B58	A23	A203	A2403	Other	Manufacturer
230	25807	6200	19831	22063	18085	15252	3962				One Lambda
774	23292	2792	15991	16908	15849	13470	2328				One Lambda
792	22320	4756	16638	17221	14013	11696	3077				One Lambda
1160	19738	2772	11862	13632	10099	8197	1630				One Lambda
1426	22688	1959	14111	16694	15184	13017	1861				One Lambda
2400	23448	5212	17370	20131	14235	11987	3360				One Lambda
3224	24959	6621	20567	21317	18205	15050	4084	24830	6282		One Lambda
3753	21434	2605	14848	16747	14253	12335	2049				One Lambda
5214	23399	6271	20425	21637	19703	17002	4161				One Lambda
8001	24988	5848	20870	21036	17056	14365	3933				One Lambda
8035	25100	2018	15521	18882	17202	14913	1945				One Lambda,
8050	22194	2342	14505	14659	15243	12698	1999				One Lambda
8062	27900	4000	19100	21600	18500	15800	3100				One Lambda
8083	22517	5780	18883	20062	16955	14553	3605				One Lambda
8096	19370	1425	11249	14127	12003	10359					One Lambda
<b>Avg</b>	23277	4040	16785	18448	15772	13380	2935	-	-		
<b>Std</b>											
<b>Dev.S</b>	2254	1849	3127	2925	2592	2275	937	-	-		
<b>MFI</b>											
<b>%CV</b>	10%	46%	19%	16%	16%	17%	32%	-	-		

**Blue** = DSA against cell #115 only

**Gold** = DSA against cell #116 only

**Green** = DSA aginst cell #115 and #116

**Table 16b. Individual laboratory results for Serum #117 - class I by Lifecodes-Immucor Single Antigen**

Ctr	**** Serum 117 ****										
	A2	A24	A68	A69	B57	B58	A23	A203	A2403	Other	Manufacturer
4661	12568	1939	7672	7120	5977	4699	930	10940	2121		Lifecodes
8029	14587	1904	8567	7539	6573	6005	1011	13630	2085		Lifecodes
8103	9088	1109	5397	3626	2848	1708	500	7301	1109		Lifecodes
<b>Avg</b>	12081	1651	7212	6095	5133	4137	814	10624	1772		
<b>Std</b>											
<b>Dev.S</b>	2782	469	1634	2148	2001	2203	275	3176	574		
<b>MFI</b>											
<b>%CV</b>	23%	28%	23%	35%	39%	53%	34%	30%	32%		



**Table 17a. Individual laboratory results for Serum #118 - class I by One Lambda Single Antigen, Cont.**

**** Serum 118 ****												
Ctr	B73	B82	A80	A36	Cw7	A1	B47	Cw5	B703	Cw15	Other	Manufacturer
230												One Lambda
774												One Lambda
792		1800			1548							One Lambda
1160	990	1087		713		736	756					One Lambda
1426	1681	2021	1896		1457							One Lambda
2400												One Lambda
3224	2346		1770	1784	2037	1890	1615	1899		1949	A24,A32,Cw2,A2403 >	One Lambda
3753	1618	1882	1758									One Lambda
5214	2751	3145	2424	2237	2184	2327		2131				One Lambda
8001	2034		1924	1783	1848	1792	1349	1536		1457	A6602,B8201	One Lambda
8035	1903	2384	1893	1079	1929	958	1181	1222				One Lambda,
8050	1638	1978	1731		1312		1055	1352				One Lambda
8062	2400	2600	1700	1300	2400	1400	1600	2300		2100	Cw2	One Lambda
8083	2104	2232										One Lambda
8096												One Lambda
<b>Avg</b>	1947	2125	1887	1483	1839	1517	1259	1740	-	1835		
<b>Std</b>												
<b>Dev.S</b>	498	572	233	555	376	601	332	436	-	336		
<b>MFI</b>												
<b>%CV</b>	26%	27%	12%	37%	20%	40%	26%	25%	-	18%		

**Blue** = DSA against cell #115 only

**Gold** = DSA against cell #116 only

**Green** = DSA against cell #115 and #116

**Table 17b. Individual laboratory results for Serum #118 - class I by Lifecodes-Immucor Single Antigen**

**** Serum 118 ****												
Ctr	B73	B82	A80	A36	Cw7	A1	B47	Cw5	B703	Cw15	Other	Manufacturer
4661		690		510					1856			Lifecodes
8029			525	596		510	552		3110		Bw6	Lifecodes
8103									1127		B40	Lifecodes
<b>Avg</b>	-	-	-	553	-	-	-	-	2031	-		
<b>Std</b>												
<b>Dev.S</b>	-	-	-	61	-	-	-	-	1003	-		
<b>MFI</b>												
<b>%CV</b>	-	-	-	11%	-	-	-	-	49%	-		





**Table 20a. Individual laboratory results for Serum #120 - class I by One Lambda Single Antigen, cont.**

**** Serum 120 ****								
Ctr	B55	B72	Cw9	Cw10	B38	B39	Other	Manufacturer
230								One Lambda
774								One Lambda
792								One Lambda
1160								One Lambda
1426	1511		1280					One Lambda
2400	2259	2063						One Lambda
3224	2158	2033	1960	1755	1323	1491		One Lambda
3753	1518							One Lambda
5214	2114	2013	2229					One Lambda
8001	1971	1934	2328	2142	1225	1361		One Lambda
8035	1849	1401	1812	1541	959	1125	B4005	One Lambda,
8050	1414	1128	1298	1149				One Lambda
8062	2200	2100	1600	1500	1400	1600	Cw15	One Lambda
8083								One Lambda
8096								One Lambda
<b>Avg</b>	1888	1810	1787	1617	1227	1394		
<b>Std</b>								
<b>Dev.S</b>	330	384	418	365	192	204		
<b>MFI</b>								
<b>%CV</b>	17%	21%	23%	23%	16%	15%		

**Blue** = DSA against cell #115 only

**Gold** = DSA against cell #116 only

**Green** = DSA against cell #115 and #116

**Table 20b. Individual laboratory results for Serum #120 - class I by Lifecodes-Immucor Single Antigen, cont.**

**** Serum 120 ****								
Ctr	B55	B72	Cw9	Cw10	B38	B39	Other	Manufacturer
4661							B703	Lifecodes
8029							B703	Lifecodes
8103							B40,B703	Lifecodes
<b>Avg</b>	-	-	-	-	-	-		
<b>Std</b>								
<b>Dev.S</b>	-	-	-	-	-	-		
<b>MFI</b>								
<b>%CV</b>	-	-	-	-	-	-		



**Table 22a. Individual laboratory results for Serum #118 - class II by One Lambda Single Antigen**

	**** Serum 118 ****											
Ctr	DQ6	DR15	DR16	DR51	DQ8	DQ9	DP401	DQA1*01	DQA1*03	Other		
230	10207	9252	5584	11426							One Lambda	
774	11182	7208	3974	10225	4510	3969					One Lambda	
792	9078	6342	3562	9438	3666	3237					One Lambda	
1160	6763	4808	2814	7272	2583	2308					One Lambda	
1426	7043	5676	2903	7862	2214	2283					One Lambda	
2400	7024	6550	4100	9823	3628	3233					One Lambda	
3224	11681	7342	4423	9881	5099	4594	1203				One Lambda	
3753	6681	5551	3026	8025	1945	1993					One Lambda	
5214	9980	8798	5590	12318	3290	3361					One Lambda	
8001	9987	6306	3395	9083	4440	3858					One Lambda	
8035	10099	9539	5170	12606	3494	2887	1289	13047	5196	DPA1*04	One Lambda	
8050	7406	6753	3624	9654	2319	1881					One Lambda	
8062	12800	9400	5100	13600	3800	4500	1200				One Lambda	
8083	11560	6797	3897	9749	5040	4532					One Lambda	
8096	10072	7668	4214	11465	3438	3085		10072	3085	DR3	One Lambda	
<b>Avg</b>	9438	7199	4092	10162	3533	3266	1231	11560	4141			
<b>Std</b>												
<b>Dev.S</b>	2009	1474	926	1818	1012	934	51	2104	1493			
<b>MFI</b>												
<b>%CV</b>	21%	20%	23%	18%	29%	29%	4%	18%	36%			

**Blue** = DSA against cell #115 only

**Gold** = DSA against cell #116 only

**Green** = DSA against cell #115 and #116

**Table 22b. Individual laboratory results for Serum #118 - class II by Lifecodes-Immucor Single Antigen**

	**** Serum 118 ****											
Ctr	DQ6	DR15	DR16	DR51	DQ8	DQ9	DP401	DQA1*01	DQA1*03	Other		
4661	3280	3850	2117	6828	1533	1091	791				Lifecodes	
8029	1446	1683	1157	3608	511						Lifecodes	
8103	2405	2081	1458	4121	728	670		2405	625	DQ3,DQA1*02,DQA1*04	Lifecodes	
<b>Avg</b>	2377	2538	1577	4852	924	881	-	-	-			
<b>Std</b>												
<b>Dev.S</b>	917	1154	491	1730	538	298	-	-	-			
<b>MFI</b>												
<b>%CV</b>	39%	45%	31%	36%	58%	34%	-	-	-			



# **Paper Challenge**

**Table 24. Individual Virtual crossmatch results for Serum #119 vs Donor# V1**

Donor #V1 HLA A\*11:01-A\*66:01-B\*41:02-B\*44:02:01G-C\*05:01-C\*17:01:01G-DRB1\*08:01-DRB1\*13:03-DRB3\*01:01-DQA1\*04:01:01G-DQA1\*05:01:01G-DQB1\*03:01-DQB1\*04:02-DPA1\*01:03:01G-DPB1\*04:01-DPB1\*06:01

Ctr	Patient	% CPRA	Virtual T Cell Prediction	Class IDSA(MFI)	Virtual B-cell prediction	Class II DSA(MFI)	Risk Assessment	Comments
54	119	98	Positive	A1101 (3123) A6601 (8793)	Positive	DR52 (1872)	Unacceptable	DSA: DQA1*05:05/ DQB1*03:01(6,417MFI)
230	119	93	Positive	A11 (3687) A66 (11296)	Positive	DQ7 (5129)	Unacceptable	
774	119	94	Positive	A1101 (2198) A6601 (9081)	Positive	DQ7 (3920)	Unacceptable	
792	119	95	Positive	A11 (2548) A66 (7580)	Positive	DQ7 (4879)	Unacceptable	
1426	119	99%	Positive	A11 (1858) A66 (4414)	Positive	DR52 (1721) DQ8 (3573)	Unacceptable	
1461	119		Positive	A11 (651) A66 (1820)	Positive	DQ7 (558)	Unacceptable	
2400	119	94%	Positive	A11 (2873) A66 (8252)	Positive	DR52 (1273) DQ7 (3869)	Unacceptable	
3224	119	97	Positive	A1101 (3818) A6601 (10404)	Positive	DR52 (1810) DQ7 (6452)	Unacceptable	
3753	119	94.82	Positive	A11 (2726) A66 (6044)				The patient also displays DSA to DRB3*01:01 (2286 MFI)
3966	119	99	Positive	A11 (4129) A66 (6127)	Positive	DQ7 (4962)	Unacceptable	
4661	119	70	Positive	A1101 (1924) A6601 (4599)	Positive	DR52 (1662) DQ7 (4770)	Unacceptable	
8001	119	95	Positive	A1101 (3117) A6601 (8196)	Positive	DR52 (1257) DQ7 (2058)	Unacceptable	151AHA, 193AV; 55PP, 57V
8029	119	26%	Positive	A11 (1461) A6601 (3353)	Positive	DR52 (1587) DQ7 (5769)	Unacceptable	B*41:02 is not included on LSAB panel
					Positive	DQ7 (843) DQ9 (784)	Unacceptable	Intermediate risk
8035	119	87%	Positive	A1101 (1971) A6601 (9562)				As per our program, this is unacceptable-- However, some programs may have other options as desensitization--if they can make sure the DSAs are not Complement binding; Our B cell Positivity is based on both Class I and II DSA.
8050	119	95	Positive	A11 (2449) A66 (5230)	Positive	DR52 (2446) DQ7 (6560)	Unacceptable	
8080	119	95	Positive	A11 (3886) A66 (11968)	Positive	DR52 (1841) DQ7 (4685)	Unacceptable	DR52 DSA allele-specific (DRB3*01:01)
8083	119	98.62	Positive	A11 (3183) A66 (9667)	Positive	DR52 (2319) DQ7 (7882)	Unacceptable	
8096	119		Positive	A11 (1639) A66 (7037)	Positive	DR52 (1814) DQ7 (5480)	Unacceptable	
				A11 (643) A66 (2034) A1101 (643) A1102 (607) A6601 (2034) A6602 (629)	Positive	DR52 (1689) DQ7 (5753) DQA1*05 (5585)	Unacceptable	
8103	119	10	Positive	(2034) A6602 (629)	Positive	DQ3 (965) DQA1*04 (663) DQA1*05 (692)	Unacceptable	Low MFI class II antibodies and class 1 positive antibodies
8111	119	83	Positive	A11 (1800) A66 (7400)	Positive	DR52 (2000) DQ7 (5000)	Unacceptable	

**Table 25. Individual Virtual crossmatch results for Serum #119 vs Donor# V2**

Donor #V2 HLA A\*02:01-A\*03:01-B\*35:03-B\*57:03-C\*04:01-C\*07:01-DRB1\*13:02-DRB3\*03:01-DQA1\*01:02-DQB1\*06:04-DPA1\*01:05-DPB1\*04:01

Ctr	Patient	% CPRA	Virtual T Cell Prediction	Class IDSA(MFI)	Virtual B-cell prediction	Class II DSA(MFI)	Risk Assessment	Comments
54	119	98	Positive	A2 (7605) B57 (16889)	Positive	DR52 (1904)	Unacceptable	
230	119	93	Positive	A2 (8882) B57 (19105)	Positive		Unacceptable	
774	119	94	Positive	A2 (6809) B57 (18267)	Positive	No Class II DSA	Unacceptable	
792	119	95	Positive	A2 (6028) B57 (15292)	Positive	No Class II DSA	Unacceptable	
1426	119	99%	Positive	A2 (4617) B57 (17096)	Positive	DR52 (1721)	Unacceptable	
1461	119		Positive	A2 (916) B57 (4657)	Positive		Unacceptable	
2400	119	94%	Positive	A2 (6549) B57 (17180)	Positive	DR52 (1351)	Unacceptable	Class II DSA is weak. Positive due to Class I reactivity.
3224	119	97	Positive	A2 (9010) B57 (19744)	Positive	DR52 (2172)	Unacceptable	
3753	119	94.82	Positive	A2 (6118) B57 (18584)	Positive		Unacceptable	The patient also displays DSA to DRB3*03:01 (2167 MFI)
3966	119	99	Positive	A2 (7204) B57 (18133)	Positive	DR52 (1662)	Unacceptable	
4661	119	70	Positive	A2 (2361) B57 (8746)	Positive	DR52 (912)	Unacceptable	62GE, 193AV, 57V
8001	119	95	Positive	A2 (7634) B57 (18124)	Positive	DR52 (1798)	Unacceptable	B*35:03, C*07:01 are not included on LSAB panel; DRB1*13:02 is not included on LSAB panel
8029	119	26%	Positive	A2 (3159) B57 (8017)	Positive	No Class II DSA	Unacceptable	No donor specific class II anti HLA antibodies
8035	119	87%	Positive	A2 (6905) B57 (20268)	Positive	DR52 (2884)	Unacceptable	As per our program, this is unacceptable-- However, some programs may have other options as desensitization--if they can make sure the DSAs are not Complement binding. Our B cell Positivity is based on both Class I and II DSA.
8050	119	95	Positive	A2 (5906) B57 (18412)	Positive	DR52 (2094)	Unacceptable	DR52 DSA allele-specific (DRB3*03:01)
8080	119	95	Positive	A2 (9618) B57 (19794)	Positive	DR52 (2558)	Unacceptable	Patient demonstrates Class I reactivity
8083	119	98.62	Positive	A2 (8030) B57 (17785)	Positive	DR52 (2248)	Unacceptable	Due to expression of Class I on B cells
8096	119		Positive	A2 (3831) B57 (17038)	Positive	DR52 (1542)	Unacceptable	
8103	119	10	Positive	A203 (860) A2 (1639) B57 (3854)	Positive	No Class II DSA	Unacceptable	Class I antibodies positive
8111	119	83	Positive	A2 (5000) B57 (16000)	Positive	DR52 (1500)	Unacceptable	

**Table 26. Individual Virtual crossmatch results for Serum #119 vs Donor# V3**

Donor #V3 HLA A\*26:01-A\*30:01-B\*13:02-B\*38:01-C\*06:02-C\*12:03-DRB1\*07:01-DRB4\*01:01-DRB4\*01:03-DQA1\*02:01-DQB1\*02:02-DPA1\*02:01-DPB1\*11:01-DPB1\*17:01

Ctr	Patient	% CPRA	Virtual T Cell Prediction	Class IDSA(MFI)	Virtual B-cell prediction	Class II DSA(MFI)	Risk Assessment	Comments
54	119	98	Positive	A26 (8353)	Positive	DR7 (5690)	Unacceptable	
230	119	93	Positive	A26 (10210)	Positive	DR7 (5877)	Unacceptable	
774	119	94	Positive	A26 (8566)	Positive	DR7 (3852)	Unacceptable	
792	119	95	Positive	A26 (6928)	Positive	DR7 (5048)	Unacceptable	
1426	119	99%	Positive	A26 (6507)	Positive		Unacceptable	
1461	119		Positive	A26 (1441)	Positive	DR7 (1170)	Unacceptable	
2400	119	94%	Positive	A26 (7468)	Positive	DR7 (5056)	Unacceptable	
3224	119	97	Positive	A26 (9895)	Positive	DR7 (5899)	Unacceptable	
3753	119	94.82	Positive	A26 (8148)	Positive	DR7 (5594)	Unacceptable	
3966	119	99	Positive	A26 (8116)	Positive	DR7 (5621) DQA1*02 (4281)	Unacceptable	
4661	119	70	Positive	A26 (4060)	Positive	DR7 (3597)	Unacceptable	193AV, 57V
8001	119	95	Positive	A26 (8485) A30 (740)	Positive	DR7 (5462)	Unacceptable	
8029	119	26%	Positive	A26 (3101)	Positive	DR7 (1591)	Unacceptable	Intermediate risk
								As per our program, this is unacceptable-- However, some programs may have other options as desensitization--if they can make sure the DSAs are not Complement binding. Our B cell Positivity is based on both Class I and II DSA.
8035	119	87%	Positive	A26 (8997)	Positive	DR7 (8417)	Unacceptable	
8050	119	95	Positive	A26 (7334)	Positive	DR7 (4685)	Unacceptable	
8080	119	95	Positive	A26 (11431)	Positive	DR7 (7911)	Unacceptable	Patient demonstrates Class I reactivity
8083	119	98.62	Positive	A26 (8859)	Positive	DR7 (5507)	Unacceptable	
8096	119		Positive	A26 (6060)	Positive	DR7 (6042)	Unacceptable	
8103	119	10	Borderline	A26 (1533)	Borderline	DR7 (1254) DQA1*02 (965)	Acceptable-	Low MFI antibody
8111	119	83	Positive	A26 (6900)	Positive	DR7 (6000)	Unacceptable	

**Table 27. Individual Virtual crossmatch results for Serum #119 vs Donor# V4**

Donor #V4 HLA A\*01:01-A\*02:01-B\*13:02-B\*52:01-C\*06:02-C\*12:02-DRB1\*07:01-DRB1\*15:02:01G-DRB4\*01:03-DRB5\*01:02-DQA1\*01:03-DQA1\*02:01-DQB1\*02:02-DQB1\*06:01-DPA1\*01:03-DPA1\*02:01-DPB1\*04:01-DPB1\*17:01

Ctr	Patient	% CPRA	Virtual T Cell Prediction	Class IDSA(MFI)	Virtual B-cell prediction	Class II DSA(MFI)	Risk Assessment	Comments
54	119	98	Positive	A2 (7605)	Positive	DR7 (5690)	Unacceptable	
230	119	93	Positive	A2 (8882)	Positive	DR7 (5877)	Unacceptable	
774	119	94	Positive	A2 (6809)	Positive	DR7 (3852)	Unacceptable	
792	119	95	Positive	A2 (6028)	Positive	DR7 (5048)	Unacceptable	
1426	119	99%	Positive	A2 (4617)	Positive	DR7 (5191)	Unacceptable	
1461	119		Positive	A2 (916)	Positive	DR7 (1170)	Unacceptable	
2400	119	94%	Positive	A2 (6549)	Positive	DR7 (5056)	Unacceptable	
3224	119	97	Positive	A2 (9010)	Positive	DR7 (5899)	Unacceptable	
3753	119	94.82	Positive	A2 (6118)	Positive	DR7 (5594)	Unacceptable	
3966	119	99	Positive	A2 (7204)	Positive	DR7 (5621) DQA1*02 (4281)	Unacceptable	
4661	119	70	Positive	A2 (2361)	Positive	DR7 (3597)	Unacceptable	62GE, 193AV, 57V
8001	119	95	Positive	A2 (7634)	Positive	DR7 (5462) DPA1*02 (550)	Unacceptable	C*12:02 is not included on LSAB panel
8029	119	26%	Positive	A2 (3159)	Positive	DR7 (1591)	Unacceptable	Intermediate risk
								As per our program, this is unacceptable-- However, some programs may have other options as desensitization--if they can make sure the DSAs are not Complement binding; Our B cell Positivity is based on both Class I and II DSA.
8035	119	87%	Positive	A2 (6905)	Positive	DR7 (8417)	Unacceptable	
8050	119	95	Positive	A2 (5906)	Positive	DR7 (4685)	Unacceptable	
8080	119	95	Positive	A2 (9618)	Positive	DR7 (7911)	Unacceptable	Patient demonstrates Class I reactivity
8083	119	98.62	Positive	A2 (8030)	Positive	DR7 (5507)	Unacceptable	Also due to expression of Class I on B cells
8096	119		Positive	A2 (3831)	Positive	DR7 (6042)	Unacceptable	
8103	119	10	Positive	A2 (1639)	Positive	DR7 (1254) DQA1*02 (965)	Unacceptable	Low MFI class 2 antibodies and positive class 1 antibodies
8111	119	83	Positive	A2 (5000)	Positive	DR7 (6000)	Unacceptable	

**Table 28. Individual Virtual crossmatch results for Serum #120 vs Donor# V1**

Donor #V1 HLA A\*11:01-A\*66:01-B\*41:02-B\*44:02:01G-C\*05:01-C\*17:01:01G-DRB1\*08:01-DRB1\*13:03-DRB3\*01:01-DQA1\*04:01:01G-DQA1\*05:01:01G-DQB1\*03:01-DQB1\*04:02-DPA1\*01:03:01G-DPB1\*04:01-DPB1\*06:01

Ctr	Patient	% CPRA	Virtual T Cell Prediction	Class IDSA(MFI)	Virtual B-cell prediction	Class II DSA(MFI)	Risk Assessment	Comments
54	120	75	Positive	B44 (14648) B41 (15949) Cw17 (8053)	Positive	No Class II DSA	Unacceptable	Positive due to Class I Positive
230	120	72	Positive	B44 (16423) B41 (22648)	-	No Class II DSA	Unacceptable	
774	120	73	Positive	B44 (15158) B41 (20935) Cw17 (10650)	Positive	No Class II DSA	Unacceptable	
792	120	77	Positive	B44 (13502) B41 (18956) Cw17 (9344)	Positive	No Class II DSA	Unacceptable	
1426	120	79%	Positive	A66 (10349) B44 (14046) B41 (19272) Cw17 (9052)	Positive	No Class II DSA	Unacceptable	
1461	120		Positive	B44 (3927) B41 (5102) Cw17 (1291)	Positive	No Class II DSA	Unacceptable	
2400	120	78%	Positive	B44 (17959) B41 (23586) Cw17 (12860)	Positive	No Class II DSA	Unacceptable	Positive due to Class I DSA.
3224	120	81	Positive	B44 (16768) B41 (22211) Cw17 (12526)	Positive	No Class II DSA	Unacceptable	
3753	120	77.93	Positive	B44 (15416) B41 (19493) Cw17 (12946)	Positive	No Class II DSA	Unacceptable	
3966	120	72	Positive	B44 (19624) B41 (23739) Cw17 (6962)	Positive	No Class II DSA	Unacceptable	B*41:02 not covered in LSAB panel
4661	120	41	Positive	B44 (8485) B41 (9266) Cw17 (2519)	Positive	No Class II DSA	Unacceptable	24T, 163EW
8001	120	85	Positive	B44 (16963) Cw5 (577) Cw17 (12600)	Positive	No Class II DSA	Unacceptable	B*41:02 is not included on LSAB panel
8029	120	24%	Positive	A66 (8208) B44 (8906) B41 (10613) Cw17 (4515)	Positive	No Class II DSA	Unacceptable	High risk
8035	120	72%	Positive	B44 (16306) B41 (22774) Cw17 (11652)				As per our program, this is unacceptable--However, some programs may have other options as desensitization--if they can make sure the DSAs are not
8050	120	82	Positive	B44 (15899) B41 (20462) Cw17 (8452)	Positive	No Class II DSA	Unacceptable	Complement binding.
8080	120	82	Positive	B44 (19610) B41 (22794) Cw17 (14727)	Positive	No Class II DSA	Unacceptable	Patient demonstrates Class I reactivity
8083	120	77.2	Positive	B44 (15002) Cw17 (12159)	Positive	No Class II DSA	Unacceptable	Possible DSA to B*41:02 but unable to determine due to no Single Antigen Bead for B*41:02; Due to expression of Class I on B cells
8096	120		Positive	A66 (8643) B44 (15949) B41 (18869) Cw17 (10140)	Positive	No Class II DSA	Unacceptable	
8103	120	22	Positive	A66 (4603) B44 (4519) B41 (4457) Cw17 (1075) A6602 (4603)	Positive	No Class II DSA	Unacceptable	Class I antibodies positive
8111	120	67	Positive	B44 (13700) B41 (19000) Cw17 (9800)	Positive	No Class II DSA	Unacceptable	

**Table 29. Individual Virtual crossmatch results for Serum #120 vs Donor# V2**

Donor #V2 HLA A\*02:01-A\*03:01-B\*35:03-B\*57:03-C\*04:01-C\*07:01-DRB1\*13:02-DRB3\*03:01-DQA1\*01:02-DQB1\*06:04-DPA1\*01:05-DPB1\*04:01

Ctr	Patient	% CPRA	Virtual T Cell Prediction	Class IDSA(MFI)	Virtual B-cell prediction	Class II DSA(MFI)	Risk Assessment	Comments
54	120	75	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
230	120	72	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
774	120	73	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
792	120	77	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
1426	120	79%	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
1461	120		Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
2400	120	78%	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
3224	120	81	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
3753	120	77.93	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
3966	120	72	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
4661	120	41	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
								B*35:03, C*07:01 are not included on LSAB panel
8001	120	85	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
8029	120	24%	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	Standard risk
8035	120	72%	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
8050	120	82	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
8080	120	82	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
8083	120	77.2	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
8096	120		Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
8103	120	22	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	
8111	120	67	Negative	No Class I DSA	Negative	No Class II DSA	Acceptable	

**Table 30. Individual Virtual crossmatch results for Serum #120 vs Donor# V3**

Donor #V3 HLA A\*26:01-A\*30:01-B\*13:02-B\*38:01-C\*06:02-C\*12:03-DRB1\*07:01-DRB4\*01:01-DRB4\*01:03-DQA1\*02:01-DQB1\*02:02-DPA1\*02:01-DPB1\*11:01-DPB1\*17:01

Ctr	Patient	% CPRA	Virtual T Cell Prediction	Class IDSA(MFI)	Virtual B-cell prediction	Class II DSA(MFI)	Risk Assessment	Comments
54	120	75	Positive	B13 (19870)	Positive	No Class II DSA	Unacceptable	Positive due to Class I Positive
230	120	72	Positive	B13 (13250)	Positive	No Class II DSA	Unacceptable	
774	120	73	Positive	B13 (22172)	Positive	No Class II DSA	Unacceptable	
792	120	77	Positive	B13 (19050)	Positive	No Class II DSA	Unacceptable	
1426	120	79%	Positive	B13 (18459)	Positive	No Class II DSA	Unacceptable	
1461	120		Positive	B13 (4746)	Positive	No Class II DSA	Unacceptable	
2400	120	78%	Positive	B13 (22957) B38 (1358)	Positive	No Class II DSA	Unacceptable	Positive due to Class I DSA.
3224	120	81	Positive	B13 (21529) B38 (1323)	Positive	No Class II DSA	Unacceptable	
3753	120	77.93	Positive	B13 (18952)	Positive	No Class II DSA	Unacceptable	
3966	120	72	Positive	B13 (18702)	Positive	No Class II DSA	Unacceptable	
4661	120	41	Positive	B13 (7560)	Positive	No Class II DSA	Unacceptable	24T, 163EW
8001	120	85	Positive	B13 (22089) B38 (988)	Positive	No Class II DSA	Unacceptable	
8029	120	24%	Positive	B13 (10007)	Positive	No Class II DSA	Unacceptable	High risk
								As per our program, this is unacceptable-- However, some programs may have other options as desensitization--if they can make sure the DSAs are not
8035	120	72%	Positive	B13 (24096) B38 (959)	Positive	No Class II DSA	Unacceptable	Complement binding.
8050	120	82	Positive	B13 (18297)	Positive	No Class II DSA	Unacceptable	
8080	120	82	Positive	B13 (22656)	Positive	No Class II DSA	Unacceptable	Patient demonstrates Class I reactivity
8083	120	77.2	Positive	B13 (20210) B38 (1100)	Positive	No Class II DSA	Unacceptable	Due to expression of Class I on B cells
8096	120		Positive	B13 (18938)	Positive	No Class II DSA	Unacceptable	
8103	120	22	Positive	B13 (2930)	Positive	No Class II DSA	Unacceptable	Class I antibody positive
8111	120	67	Positive	B13 (19500)	Positive	No Class II DSA	Unacceptable	

**Table 31. Individual Virtual crossmatch results for Serum #120 vs Donor# V4**

Donor #V4 HLA A\*01:01-A\*02:01-B\*13:02-B\*52:01-C\*06:02-C\*12:02-DRB1\*07:01-DRB1\*15:02:01G-DRB4\*01:03-DRB5\*01:02-DQA1\*01:03-DQA1\*02:01-DQB1\*02:02-DQB1\*06:01-DPA1\*01:03-DPA1\*02:01-DPB1\*04:01-DPB1\*17:01

Ctr	Patient	% CPRA	Virtual T Cell Prediction	Class IDSA(MFI)	Virtual B-cell prediction	Class II DSA(MFI)	Risk Assessment	Comments
54	120	75	Positive	B13 (19870)	Positive	No Class II DSA	Unacceptable	Positive due to Class I Positive
230	120	72	Positive	B13 (22360)	Positive	No Class II DSA	Unacceptable	
774	120	73	Positive	B13 (22172)	Positive	No Class II DSA	Unacceptable	
792	120	77	Positive	B13 (19050)	Positive	No Class II DSA	Unacceptable	
1426	120	79%	Positive	B13 (18459)	Positive	No Class II DSA	Unacceptable	
1461	120		Positive	B13 (4746)	Positive	No Class II DSA	Unacceptable	
2400	120	78%	Positive	B13 (22957)	Positive	No Class II DSA	Unacceptable	Positive to Class I DSA.
3224	120	81	Positive	B13 (21529)	Positive	No Class II DSA	Unacceptable	
3753	120	77.93	Positive	B13 (18952)	Positive	No Class II DSA	Unacceptable	
3966	120	72	Positive	B13 (18702)	Positive	No Class II DSA	Unacceptable	
4661	120	41	Positive	B13 (7560)	Positive	No Class II DSA	Unacceptable	24T, 163EW
								C*12:02 is not included on LSAB panel; DRB5*01:02 is not included on LSAB panel
8001	120	85	Positive	B13 (22089)	Positive	No Class II DSA	Unacceptable	
8029	120	24%	Positive	B13 (10007)	Positive	No Class II DSA	Unacceptable	High risk
								As per our program, this is unacceptable-- However, some programs may have other options as desensitization--if they can make sure the DSAs are not
8035	120	72%	Positive	B13 (24096)	Positive	No Class II DSA	Unacceptable	Complement binding.
8050	120	82	Positive	B13 (18297)	Positive	No Class II DSA	Unacceptable	
8080	120	82	Positive	B13 (22656)	Positive	No Class II DSA	Unacceptable	Patient demonstrates Class I reactivity
8083	120	77.2	Positive	B13 (20210)	Positive	No Class II DSA	Unacceptable	Due to expression of Class I on B cells
8096	120		Positive	B13 (18938)	Positive	No Class II DSA	Unacceptable	
8103	120	22	Positive	B13 (2930)	Positive	No Class II DSA	Unacceptable	Class I antibody positive
8111	120	67	Positive	B13 (19500)	Positive	No Class II DSA	Unacceptable	



